ArticleBMC biology2026
PepPharmaHub: a cloud-based platform integrating multimodel language architectures with curated data resources for therapeutic peptide discovery.
Article in BMC biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapeutic peptides represent a rapidly expanding class of drug candidates due to their diverse biological activities and high specificity. However, accurately predicting peptide functions directly from sequence information remains a major challenge in computational peptidomics. Current tools, typically standalone applications or functionally constrained web servers, lack the flexibility and scalability essential for modern peptide discovery workflows. Therefore, it is necessary to develop a cloud-based, no-code platform that enables customizable modeling and high-throughput functional screening of therapeutic peptides.
resultsPepPharmaHub provides a cloud-based, end-to-end platform that integrates advanced sequence-based language modeling with curated benchmark datasets and interactive visualization modules. The platform features a high-throughput screening module powered by a diverse set of 24 models targeting 20 therapeutic properties, alongside a customizable model training pipeline for user-defined screening tasks. Comprehensive benchmarking on 24 public datasets demonstrates that PepPharmaHub matches or surpasses state-of-the-art predictors, significantly improving the efficiency of large-scale peptide screening. Compared with existing public web servers, PepPharmaHub attains a higher, more tightly distributed accuracy on 3475 newly reported bioactive peptides from 1 January 2023 to 1 June 2025 (20 independent tasks), indicating stronger generalization and practical utility.
conclusionsPepPharmaHub enables accurate, high-throughput prediction of peptide functions through customizable deep learning models and a no-code interface. By outperforming existing tools across multiple benchmarks and supporting interpretable sequence analysis, the platform offers a practical solution for accelerating peptide-based drug discovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.